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Abstract Acute myocardial infarction resulting from
saphenous vein graft occlusion occurs not infrequently in
patients who have undergone coronary artery bypass graft
surgery. In this case report, we present a novel case of
spontaneous recanalization of a thrombotic graft occlusion
in a patient who presented with a subacute myocardial
infarction. The patient was treated medically with aspirin
as the only anti-platelet agent. Interestingly, he presented
2 months later with new onset angina. Coronary angiog-
raphy demonstrated complete resolution of thrombus but a
severe focal stenosis in the distal anastomoses. Following
drug eluting stent placement, a favorable clinical course
has ensued and patency conﬁrmed on follow up angiog-
raphy at 1 year.
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Introduction
Approximately 400,000 coronary artery bypass graft
(CABG) surgeries are performed in the United States each
year [1]. As these grafts age, patients are at high cumula-
tive risk for developing new cardiovascular events due to
graft occlusion. Studies have suggested that saphenous vein
graft (SVG) occlusion occurs at a rate of approximately
10% in the ﬁrst month and up to 20% in the ﬁrst year, with
a 2% annual risk for the ﬁrst 5 years [2]. Recurrent
infarction may occur in as many as 29% of patients in
10 years following CABG [3]. In contrast to SVGs, the left
internal mammary artery (LIMA) graft has a 10% closure
rate in 10 years. Of note, at least 10% of percutaneous
coronary interventions (PCI) are currently performed in
saphenous vein grafts (SVG) lesions [1]. When patients
with prior CABG present with chronically occluded SVG,
the options are often limited due to the suboptimal clinical
results in recanalizing these grafts percutaneously. These
patients usually have 3 options: (1) percutaneous coronary
intervention of the severely diseased native vessels, (2)
repeat CABG or (3) medical therapy alone.
We present an unusual case of a patient presenting with
a total occlusion of a SVG which spontaneously recanal-
ized over a 2 month period but with a persistent focal
stenosis at the distal anastomosis. The distal anastomotic
stenosis was treated with a drug eluting stent and the vessel
remained patent angiographically at 1 year.
Case report
The patient is a 76 year old gentleman with a history of
known arteriosclerotic heart disease, status post CABG in
June 1989 with a LIMA graft to the left anterior descending
artery and separate SVGs to the diagonal branch and right
coronary arteries. He developed recurrent angina and
subsequently had a bare metal stent placed in the native left
circumﬂex coronary artery in 2002. In 2005, he developed
atypical chest pain and a sestamibi scan showed antero-
lateral ischemia. He underwent repeat coronary angiogra-
phy which showed patent grafts and he was managed
medically.
P. P. Hu  K. L. Peterson  S. Tsimikas
Division of Cardiovascular Diseases, University of California,
San Diego, USA
S. Tsimikas (&)
Vascular Medicine Program, University of California San Diego,
9500 Gilman Drive, BSB 1080, La Jolla, CA 92093-0682, USA
e-mail: stsimikas@ucsd.edu
123
J Thromb Thrombolysis (2009) 28:101–105
DOI 10.1007/s11239-009-0339-xFour days prior to the January 2007 admission, he
developed acute onset retrosternal chest pain that was
associated with fatigue. It lasted approximately 2 h and
relieved by sublingual nitroglycerin. He subsequently
developed atypical chest discomfort as well as exercise
intolerance. He presented to medical care 4 days later with
a blood pressure of 135/80, pulse of 80 pulse and normal
chest, heart and vascular exam. An electrocardiogram
revealed loss of anterior forces, new right axis deviation and
borderline 1 mm of ST elevation in leads I and AVL. The
troponin-I level was elevated at 7.9 ng/ml. Lipid proﬁle
showed total cholesterol 171, triglyceride 103, HDL 48,
LDL 102. He was treated with intravenous heparin and
eptiﬁbatide and referred for urgent coronary angiography.
He was maintained on aspirin 81 mg/day and ramipril that
he was already taking and started on isosorbide mononi-
trate, metoprolol and ezetimibe/simvastatin. Subsequent
troponin levels decreased and the clinical diagnosis was
acute coronary syndrome with recent myocardial infarction.
Coronary angiography showed complete thrombotic
occlusion of the SVG to the diagonal branch (Fig. 1), with
patent SVG to the right coronary artery with jump to the
posterolateral branch. The SVG to the diagonal branch was
large and completely ﬁlled with thrombus which was dis-
tinguished by multiple swirling ﬁlling defects. There was a
faint trickle of ﬂow in the graft body of the diagonal branch
but the contrast did not reach the native diagonal branch.
The LIMA to the LAD was patent. Left ventriculography
showed new evidence of anterolateral and apical akinesis
and there was a 1 to 2? mitral regurgitation. Because this
was felt to be a functionally occluded SVG with a myo-
cardial infarction approximately 5 days old, with no
recurrent ischemia or other indication for revascularization,
the eptiﬁbatide was discontinued after the procedure after a
total duration of approximately 3 h and the patient was
treated medically and discharged on aspirin 81 mg/d as the
only anti-platelet agent.
Two months after the initial hospitalization the patient
developed chest tightness lasting approximately 45 min
associated with diaphoresis and shortness of breath. ECG
revealed markedly inverted T-waves in leads I and AVL as
well as in leads V4–V6 which were new compared to his
ECG previously. Troponin levels were normal. He was
treated with heparin and eptiﬁbatide for approximately 4 h
prior to being taken to the cardiac catheterization labora-
tory. Repeat angiography showed complete patency of the
previously occluded SVG to the diagonal branch (Fig. 2)
with complete angiographic resolution of the thrombus.
However, there was a focal 95% stenosis at the distal
anastomosis, for which a drug eluting stent (3.0 9 18 mm
Cypher, Cordis, Miami, Florida) was placed. The proximal
segment of this stent that was in the bypass graft was
treated with a 4.0 9 8 mm Quantum balloon (Boston
Scientiﬁc, Maple Grove, Minnesota) and expanded to 16
atmospheres. The patient had transient chest discomfort
during the procedure that reproduced his angina. He sub-
sequently had complete resolution of angina and was
treated with aspirin and clopidogrel indeﬁnitely.
One year later the patient had another episode of resting
but somewhat atypical chest pain and was admitted to the
hospital. Initial ECG was unchanged, however T wave
inversions were noted in V2, V3, and patient was taken to
the catheterization laboratory. Angiography demonstrated
no signiﬁcant change from the prior cardiac catheteriza-
tion, including a patent SVG-to-diagonal graft with no
Fig. 1 Initial angiogram in January of 2007 shows complete
occlusion of the SVG to diagonal branch. The white arrow points
to the area of occlusive thrombus seen near the ostium of the SVG.
Two views are shown (LAO cranial, RAO cranial)
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123in-stent restenosis (Fig. 3). The patient has no evidence of
ischemia 24 months following the stent placement.
Discussion
This report demonstrates the rare phenomenon of complete
angiographic thrombus resolution and reperfusion of a
thrombotically occluded SVG following treatment with
aspirin as the only outpatient anti-platelet therapy. Fur-
thermore, the SVG had documented 1 year patency
following drug eluting stent placement at the presumed site
of thrombotic occlusion and a favorable clinical course for
2 years. This case suggests that a subset of patients may
have the physiological capability for spontaneous ﬁbrino-
lysis of even very large thrombi in completely occluded
SVGs. It also reﬂects the therapeutic efﬁcacy of PCI and
drug eluting stents in maintaining graft patency, at least in
the near term.
Vein graft infarctions usually occur in degenerated vein
grafts ﬁlled with atherothrombotic debris. Their greater
content of thrombus and other material such as necrotic
debris predisposes them to a greater propensity for graft
Fig. 2 Repeat angiogram performed 2 months later when the patient
presented with more symptoms and negative cardiac markers. LAO
cranial and caudal views shown here with white arrow demonstrating
stenotic occlusion at the anastomosis site
Fig. 3 Follow up angiography 1 year later demonstrating patent SVG
to diagonal-branch with patent Cypher stent. Angiography is
performed in LAO and RAO cranial views with angulation similar
to Fig. 1
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123trauma, distal embolization and no-reﬂow phenomenon
after an intervention. In the patient described in this report,
repeat angiography 2 months following the initial angio-
gram demonstrated that the infarct related SVG was patent.
Although the patient received four hours of eptiﬁbatide
prior to angiogram, it is unlikely that this had a signiﬁcant
‘‘thrombolytic’’ effect as the SVG was totally occluded
during prior coronary angiography. Prior studies in ACS or
STEMI involving SVGs have not generally shown any
beneﬁt from IIb/IIIa inhibitors or even thrombolytic ther-
apy [4, 5]. For example, in the Mayo Clinic PCI Registry
[6], results from 128 patients with prior CABG with pri-
mary PCI in AMI patients showed that when the treated
vessel was a SVG, there was a lower success rate, with
increased inability to completely recanalize the SVG along
with increased risk of distal embolization, when compared
to a native vessel intervention. Similarly, in the PAMI-2
trial where the infarct related artery was an SVG rather
than a native coronary artery, both TIMI-3 ﬂow grade
(70.2% vs. 94.3%) and 6-month mortality (14.3% vs. 4.1%)
were worse in patients with versus without previous CABG
[7]. Similar outcomes were noted in the GUSTO-I trial in
1784 patients with STEMI [8]. Nonetheless, in a subset of
patients, such as the one presented here, they may enhance
partial ﬁbrinolysis as has been suggested by upfront IIb/IIIa
inhibitor use in STEMIs showing enhanced TIMI III ﬂow
on angiography prior to PCI [9]. It is intriguing to speculate
that this process may be enhanced by novel anti-platelet
agents that are being developed [10].
In SVG infarct cases, the decision to proceed to an
intervention is made after taking into consideration infarct
size and duration, patient condition, thrombus burden, and
vessel anatomy. Recanalization of the native coronary
artery to which the SVG was anastomosed may be a better
option. In our case, no initial intervention was performed
for the occluded SVG due to the large thrombus burden in
the length of the graft and the regression of symptoms.
Furthermore the native diagonal branch was totally occlu-
ded proximally and it was felt that it could not be
recanalized.
Only two previous cases have been reported of sponta-
neous reperfusion of a SVG related to an AMI. The ﬁrst is a
patient with a NSTEMI due to SVG thrombosis 1 month
after discontinuation of antiplatelet therapy [11]. The graft
was initially ﬁlled with thrombus but was patent 6 days
later. The second case is a patient with a STEMI due to an
occlusion of one SVG, who was treated with a stent to his
native LAD. Three months later the graft was patent but the
native LAD occluded [12]. Our case represents the longest
documented patency of a spontaneously recanalized graft,
albeit it was also treated with a drug eluting stent at the
distal anastomosis which likely has helped maintain
patency. Spontaneous reperfusion of an infarct related
native coronary artery is not uncommon, particularly in this
era of aggressive in-hospital anti-thrombotic therapy, and is
associated with greater myocardial salvage and resolution
of chest pain [13].
This observation of ‘‘spontaneous’’ reperfusion is
highly intriguing, particularly in an elderly individual, an
age group where impaired ﬁbrinolysis is common [14]. It
is possible that aspirin by itself potentiated a ﬁbrinolytic
effect, as demonstrated in the ISIS-2 thrombolytic trial
where the aspirin alone was associated improved clinical
outcomes [15]. It has also been reported that the local
proﬁbrinolytic response in coronary arteries, by net coro-
nary release of tissue—type plasminogen activator (t-PA)
following induced myocardial ischemia in pigs, could be a
useful defense against coronary thromboembolic events.
In fact, higher levels of t-PA are noted in ST-segment
elevation myocardial infarction, and are paradoxically
associated with worse prognosis [16, 17]. Possible mech-
anisms of spontaneous recanalization include the release
of factors, activators and inhibitors of ﬁbrinolysis, from
the endothelium, neutrophils and monocytes [18]. The role
of thienopyridines such as clopidogrel in enhancing
reperfusion has not been demonstrated, but one would
predict it would be additive to aspirin, based on recent
trials [19].
In conclusion, we describe an unusual case of sponta-
neous reperfusion of an SVG, subsequent treatment of a
residual stenosis with a drug eluting stent and a favorable
2 year outcome. Understanding the underlying mecha-
nisms of enhanced thrombolysis may help discover new
insights into sustained graft patency that may improve long
term outcomes of patients undergoing CABG. Although it
has not been formally evaluated yet, deﬁning the long-term
efﬁcacy of dual anti-platelet therapy in patients in pre-
venting events in patients who have undergone CABG is a
worthwhile clinical question that should be investigated.
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